GenSight Biologics S.A. (SIGHT) is a Biotechnology company in the Healthcare sector, listed on Euronext Paris. This page provides the complete earnings calendar, dividend schedule, and financial data for GenSight Biologics S.A. in 2026. The next earnings report is expected on September 29, 2026.
Next earnings date
29 Sep 2026
In 40 days
EPS estimate
—
Revenue estimate
—
Past earnings
Latest earnings analysis
No consensus estimates were available to compare, and GenSight Biologics posted EPS of USD -0.0589 and revenue of USD -235.6 thousand. There is no prior report available for comparison.
No dividend history available.
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
GenSight Biologics S.A. (SIGHT) is scheduled to report earnings on September 29, 2026.
GenSight Biologics S.A. (SIGHT) last reported earnings on September 29, 2025.
GenSight Biologics S.A. (SIGHT) is listed on Euronext Paris.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.